Recent news on Rescriptor

HIV resistance mutations common but CXCR4 rare among untreated US ...  -  May 22, 2007
Aidsmap,Resistance to nevirapine (Viramune), delavirdine (Rescriptor), stavudine (Zerit), efavirenz (Sustiva), zidovudine (Retrovir), and nelfinavir (Viracept) were

Some HIV Drugs May Up Heart Risk  -  Apr 25, 2007
WebMDExamples of this type of drug include Viramune, Sustiva, and Rescriptor. The study doesn't prove that protease inhibitors cause heart attacks.

Some HIV Drugs May Up Heart Risk  -  26 Apr 2007
WebMDExamples of this type of drug include Viramune, Sustiva, and Rescriptor. The study doesn't prove that protease inhibitors cause heart attacks.

CROI 2007: A great leap forward  -  Mar 21, 2007
NAPWA,But there are only three approved drugs in the class – nevirapine (Viramune), efavirenz (Stocrin) and the rarely-used delavirdine (Rescriptor) – and they

AIDS Group Bans Pfizer Sales Reps  -  Feb 8, 2007
Forbes,Pfizer also sells the HIV drugs Viracept and Rescriptor. The company, which didn't break out sales of the drugs in their most recent quarterly report,

National business briefs  -  Feb 9, 2007
NorthJersey.com,Pfizer, the world's largest drug maker, sells two HIV products, Rescriptor and Viracept, and is seeking US regulatory approval for a third.

Merck, Pfizer HIV Drugs May Spark a Second Revolution (Update1)  -  Feb 15, 2007
BloombergK103N allows viruses to resist not only Bristol's Sustiva, but the whole class of drugs related to it, including Pfizer's Rescriptor and Viramune,

Updated HIV Treatment Guidelines Now Include Three GSK HIV ...  Aug 13, 2006
R) (cisapride), Versed(R) (midazolam), Orap(R) (pimozide), Zocor(R) (simvastatin), Mevacor(R) (lovastatin), Rifadin(R) (rifampin), Rescriptor(R) (delavirdine ... -International News Service

Updated HIV treatment guidelines now include three GSK HIV ...  Aug 14, 2006
...cisapride), Versed® (midazolam), Orap® (pimozide), Zocor® (simvastatin), Mevacor® (lovastatin), Rifadin® (rifampin), Rescriptor® (delavirdine mesylate ... -WebWire



Multi-component drug delivery system: An emerging trend  Feb 8, 2006
Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs), which include delavirdine (Rescriptor), efavirenz (Sustiva), and nevirapine (Viramune). ... - Express Pharma Pulse

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional